Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | MMP12 | P39900 | 2/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | FABP7 | O15540 | 1/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305170 | 0.98 | EPHX1 (0.41) | EPHX1HTTCYP2C19NAAACYP19A1 | |
| SCHEMBL2719403 | 0.94 | EPHX1 (0.37) | EPHX1HTTCYP2C19NAAACYP19A1 | |
| SCHEMBL6007716 | 0.85 | EPHX1 (0.46) | EPHX1HTTCYP2C19NAAACYP19A1 | |
| SCHEMBL2956734 | 0.84 | EPHX1 (0.42) | EPHX1HTTCYP2C19NAAACYP19A1 | |
| SCHEMBL4248940 | 0.82 | EPHX1 (0.43) | EPHX1HTTCYP2C19NAAACYP19A1 | |
| SCHEMBL6007723 | 0.81 | EPHX1 (0.46) | EPHX1HTTCYP2C19NAAACYP19A1 | |
| SCHEMBL305711 | 0.80 | L3MBTL1 (0.35) | L3MBTL1 | |
| SCHEMBL8426647 | 0.79 | EPHX1 (0.60) | EPHX1HTTCYP2C19NAAACA12 | |
| SCHEMBL13387598 | 0.79 | EPHX1 (0.60) | EPHX1HTTCYP2C19NAAACA12 | |
| SCHEMBL11589654 | 0.79 | EPHX1 (0.60) | EPHX1HTTCYP2C19NAAACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464952-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180291039-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-11 | — | — | US | disclosed |
| WO-2017100537-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2017-06-15 | — | — | WO | disclosed |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | MEIJI SEIKA KAISHA (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9260375-B2 | Metallo-β-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-8344154-B2 | 2-thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | CHIKAUCHI KEN (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8093294-B2 | Bacterial infections; effective for recovering the activities of beta-lactam antibiotics; 2-ethyl-3-methylmaleic acid dimethyl ester; maleic acid derivatives and/or dihydrofuranyl derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-20100145063-A1 | 2- thioethenyl substituted carbapenem derivatives | MARUYAMA TAKAHISA | 2010-06-10 | — | — | US | disclosed |
| US-7687490-B2 | 2-thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| WO-1997041098-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-11-06 | — | — | WO | disclosed |
| WO-1997021675-A1 | MONOCYCLIC BETA-LACTAME DERIVATIVES FOR TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-06-19 | — | — | WO | disclosed |
| US-5612477-A | 2-(pyrazol-3-yl)carbapenem derivatives | SMITHKLINE BEECHAM P.L.C | 1997-03-18 | — | — | US | disclosed |
| US-5606051-A | 2-(pyrazol-3-yl)carbapenem derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-02-25 | — | — | US | disclosed |
| EP-0725783-A1 | 2-(PYRAZOL-3-YL)CARBAPENEM DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1996-08-14 | — | — | EP | disclosed |
| WO-1995011905-A1 | 2-(PYRAZOL-3-YL)CARBAPENEM DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1995-05-04 | — | — | WO | disclosed |
| WO-1993019067-A1 | IMIDAZOPYRIDINE DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-09-30 | — | — | WO | disclosed |
| US-5120841-A | Antibiotics for easy absorption | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-06-09 | — | — | US | disclosed |
| EP-0128029-B1 | CEPHALOSPORIN ESTER DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1989-02-08 | — | — | EP | disclosed |
| EP-0128029-A2 | Cephalosporin ester derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1984-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145063-A1 | 2- thioethenyl substituted carbapenem derivatives | MTAP, BLVRB, TPMT | EPHX1 4523/4885HTT 3272/4885CYP2C19 239/4885 |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ME1, MGAM, GAA | EPHX1 3070/4885HTT 4870/4885CYP2C19 670/4885 |
| US-10464952-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | EPHX1 1252/4885HTT 4789/4885CYP2C19 701/4885 |
| US-20180291039-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | EPHX1 1252/4885HTT 4789/4885CYP2C19 701/4885 |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | ME1, MGAM, MANBA | EPHX1 3262/4885HTT 4875/4885CYP2C19 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.